Literature DB >> 1942311

The growth of MAT-LyLu rat prostatic adenocarcinoma can be prevented in vivo by polyamine deprivation.

J P Moulinoux1, V Quemener, B Cipolla, F Guillé, R Havouis, C Martin, B Lobel, N Seiler.   

Abstract

The combination of inhibitors of ornithine decarboxylase and polyamine oxidase, and of antibiotics suitable for the (partial) decontamination of the gastrointestinal tract, with a polyamine deficient diet, is responsible for the almost complete inhibition of the growth of MAT-LyLu prostatic adenocarcinoma. In the tumor-bearing animals, erythrocyte spermidine levels were reduced, but spermine concentrations were increased. As has been previously observed, the increase in erythrocyte spermine level was associated with an enhancement of malignant cell death. Adriamycin administration did neither diminish tumor growth, nor potentiate the antitumor effect of polyamine deprivation treatment. Interruption of the polyamine deprivation treatment was accompanied by a significant enhancement of tumor growth. Since polyamine deprivation causes only reversible growth inhibition, it seems not appropriate as a monotherapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1942311     DOI: 10.1016/s0022-5347(17)38125-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide.

Authors:  B Cipolla; Y Blanchard; L Chamaillard; V Quemener; F Guillé; R Havouis; J P Moulinoux
Journal:  Urol Res       Date:  1996

2.  Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment.

Authors:  Candace S Hayes; Allyson C Shicora; Martin P Keough; Adam E Snook; Mark R Burns; Susan K Gilmour
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

3.  The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.

Authors:  Anne R Simoneau; Eugene W Gerner; Ray Nagle; Argyrios Ziogas; Sharon Fujikawa-Brooks; Hagit Yerushalmi; Thomas E Ahlering; Ronald Lieberman; Christine E McLaren; Hoda Anton-Culver; Frank L Meyskens
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

Review 4.  One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling.

Authors:  Joshua M Corbin; Maria J Ruiz-Echevarría
Journal:  Int J Mol Sci       Date:  2016-07-27       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.